Table 1.

CRISPR Clinical Trials at time of debate

NCT ID	Phase	Intervention	Conditions Targeted	Study Sponsor
NCT03057912	I	TALEN- or CRISPR/Cas9- mediated disruption of HPV E6/E7 DNA	Human Papillomavirus-Related Malignant Neoplasm	First Affiliated Hospital, Sun Yat-Sen University
NCT0381715	II	Autologous CRISPR/Cas9-engineered PD-1 knockout-T cells	Esophageal Cancer	Hangzhou Cancer Hospital
NCT03044743	I/II	Autologous CRISPR/Cas9-engineered PD-1 knockout-T cells	Stage IV Gastric Carcinoma; Stage IV Nasopharyngeal Carcinoma; T-Cell Lymphoma Stage IV; Stage IV Adult Hodgkin Lymphoma; Stage IV Diffuse Large B-Cell Lymphoma	Yang Yang, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NCT02793856	I	Autologous CRISPR/Cas9-engineered PD-1 knockout-T cells	Metastatic Non-small Cell Lung Cancer	Sichuan University
NCT02867332	I	Autologous CRISPR/Cas9-engineered PD-1 knockout-T cells	Metastatic Renal Cell Carcinoma	Peking University
NCT02867345	I	Autologous CRISPR/Cas9-engineered PD-1 knockout-T cells	Hormone Refractory Prostate Cancer	Peking University
NCT02863913	I	Autologous CRISPR/Cas9-engineered PD-1 knockout-T cells	Invasive Bladder Cancer Stage IV	Peking University
NCT03164135	–	CRISPR/Cas9 CCR5 gene modification of CD34+ hematopoietic stem cells	HIV-1-infection Hematological Malignancies	Affiliated Hospital to Academy of Military Medical Sciences
NCT03166878	I/II	Autologous CRISPR/Cas9-engineered universal CD19-specific CAR-T cells	B Cell Leukemia; B Cell Lymphoma	Chinese PLA General Hospital